Вы находитесь на странице: 1из 45

..


()



5

4-24



50-70%

,



29%
29%

1 65 *
2

527
0001,

2 2,b
*

2
25 2,b

,2


111 2,b


5 3
* 5
a 2008 2001-2011.
b 19862000.
1. Tate JE et al. Lancet Infect Dis. 2012;12:136141.
2. Parashar UD et al. Emerg Infect Dis. 2003;9:565572.
3. Glass RI et al. Lancet. 2006;368:323332.


35

40% (35%-45%)
< 5

,

!
Weekly epidemiological record. No. 47, 2008, pp. 421425.

,
:


1. Bernstein DI. Pediatr Infect Dis J. 2009;28:S50S53. (


Wolters
5
Kluwer Health)




,


44-47%
5
2011 3


90 (
- 60
)
6

2 ( 1-7 )
:

: 39

1. Ramig RF. Expert Rev Anti Infect Ther. 2007;5:591612. 2. Boshuizen


JA et al. J
8
Virol. 2003; 77: 1300513016. Boshuizen JA et al,


-
10 /

10
/3





, ,


2 10
9

:
24

~40%
3
2

100%

1-

80%
2-

60%
40%

3-

20%

4-
5-

0
0

10

1 14 1 18 20 22 24
6
N=200
2()

Velzquez FR et al. N Engl J Med. 1996;335:10221028. From N Engl J Med,


Velazquez FR et al, Rotavirus infections in infants as protection against
subsequent infections, Vol 335, p1022-1028 1996 Massachusetts
10 Medical
Society. Massachusetts Medical Society.


(%)

(, N=200)
100
90
80
70

60
50

40
30

20
10
0

1
1-

2-

3-

Velzquez FR et al. N Engl J Med. 1996;335:10221028. 2. Velzquez


FR et al. J
11
Infect Dis. 2000;182:16021609. Oxford University Press.


11

G (VP7)

P- (VP4)


(VP2)

(VP6)

Virus Res, Vol. 101, Issue 1, Jayaram H et al, Emerging themes in rotavirus cell entry, genome
organization,
12
transcription and replication, . 67-81, 2004 ( Elsevier)

:
A, B, C

:
D, E, F, G


VP4
(P )

P :P

1:>1

VP7
(G )

G = G

1:1

13

G2:

5
2
,

Wa
DS-1
G1P[8]
G2P[4]

G3P[8]
G4P[8]
G9P[8]
Gentsch JR et al. J Infect Dis. 2005;192:S146S159.

14


,
G P


,

5
:
G1P[8], G2P[4], G3P[8], G4P[8], G9P[8]


()
1. Santos N et al. Rev Med Virol. 2005;15:2956.
2. Velzquez FR et al. N Engl J Med. 1996;355:10221028.

15

:

(1996 2007)1
G1P[8]

G2P[4]

G3P[8]

G4P[8]

G9P[8]

1. Banyai K et al. Vaccine. 2012;30S:A122A130.

16




2005-2007

2011-2012

95% 5 : G1, G2, G3, G4, G9





1. Adapted from: Podkolzin AT et al. Hospital-Based Surveillance of Rotavirus and Other Viral Agents of Diarrhea in Children and Adults
in Russia, 20052007. The Journal of Infectious Diseases 2009; 200:S22833
2. Adapted from EPMG Report: Rotavirus grA surveillance and genotype distribution in Russian Federation in season 2011-2012 Podkolzin A.T., Petukhov D.N., Veselova
O.A.Central Research Institute of Epidemiology, EPMG (Enteric Pathogens Monitoring Group/RF) Moscow, Russian Federation (accessed June 12, 2012)
3. Griffin DD, et al. J Clin Microbiol. 2000;38:27842787
4.


, , ,


.
!

.


.


,

, 2012

18


, ,
,


6 12 ,

4

.


19


,32
2012

()

()

4,5

++

()
++


6

4



1. Rotavirus vaccines. WHO position paper January 2013. No. 5, 2013, 88, 4964.
http://www.who.int/wer



(REST):
68 038
34 035 , 34 003

, :
81 (0.2%) : 97 (0.3%)
22
, REST Rotavirus Efficacy and Safety Trial; -


(REST):


n=68 038 (34 035 -;
34 003 )

n=9 605
(4 806 - ;
4 799 )


n=5 673 (2 834
; 2 839
)

:
,


;+

+
,

REST Rotavirus Efficacy and Safety Trial. Vesikari T et al. N Engl J Med.
2006;354:2333.

98%

74%

(N=5 673: 2 834


;
2 839 )
(N=5 673:
2 834 ; 2 839
)

2 :

~95%



(N=68 038: 34 035 ; 34
003 )

REST Rotavirus Efficacy and Safety Trial. Vesikari T et al. N Engl J Med.
2006;354:2333.

III:

(n=36,165)
(%)

(n=35,560)
(%)

0.6

0.7

0.2

0.3

0.2

0.2

0.1

0.1

0.1

0.1

52 (25 ,
27 );

(8 , 9 ) 25

III:

42

(n=6 138)

%
(n=5 573)
%

24,1
21,3

15,2

13,6

14,5

13,0

10,5

10,1

6,9

5,8

26









85 150 ,
1

,

(n=62 167)

=
27


41

: 10 ,




2,5

1, 5 -
,
, 20%
5

http://apps.who.int/gb/ebwha/pdf_files/EB128/B128_9-ru.pdf


.
2013

Rotavirus vaccines. WHO position paper January 2013. No. 5, 2013, 88, 4964. http://www.who.int/wer





41

, ,
:
1. 70-90%
2. 50% 20-40%

3. 15-70%
,



:

/




, ,
.



.



( 2
)

() - 3
-




- Vibrio cholerae O1 O139

- (

- 14

-
-
-



!!!
,
2 :
(, )


(> 2 )


!!!
,
2 :
,

,


( )

,

.
.
5


( )

.
(/ ).

/ +


:


0,9% NaCl
!!! (
)


( )
100 /


70 /
:

< 12

30 /
:
1

12

30 a

: +
+ +


( )



4 ;
,

~ 50 /

4-12

12 24

2 - 5

<6

6 - <10

10 <12

12-19

200-400

400-700

700-900

900-1400


( )

4 :
1.
2. * ( )
3.
4.
:



,


,
: , ( , ,
),

< 2 : 50 100

2 : 100-200


()
- 15 / 2
3
- / / 50-80 //
3
/